These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7830026)

  • 1. The cost-effectiveness of a cardiovascular multiple-risk-factor intervention programme in treated hypertensive men.
    Johannesson M; Agewall S; Hartford M; Hedner T; Fagerberg B
    J Intern Med; 1995 Jan; 237(1):19-26. PubMed ID: 7830026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of multiple risk factor intervention in treated hypertensive men during long-term follow up. Risk Factor Intervention Study Group.
    Agewall S; Wikstrand J; Samuelsson O; Persson B; Andersson OK; Fagerberg B
    J Intern Med; 1994 Dec; 236(6):651-9. PubMed ID: 7989900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of quality of life during multiple risk factor intervention in treated hypertensive men at high cardiovascular risk.
    Agewall S; Wikstrand J; Dahlöf C; Fagerberg B
    J Hypertens; 1995 Dec; 13(12 Pt 1):1471-7. PubMed ID: 8866910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
    Jönsson B; Carides GW; Burke TA; Dasbach EJ; Lindholm LH; Dahlöf B;
    J Hypertens; 2005 Jul; 23(7):1425-31. PubMed ID: 15942467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of treating hypertension in elderly people--an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension).
    Johannesson M; Dahlöf B; Lindholm LH; Ekbom T; Hansson L; Odén A; Scherstén B; Wester PO; Jönsson B
    J Intern Med; 1993 Sep; 234(3):317-23. PubMed ID: 8354983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicomponent intervention versus usual care for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: study protocol for a cluster randomized controlled trial.
    Jafar TH; Jehan I; de Silva HA; Naheed A; Gandhi M; Assam P; Finkelstein EA; Quigley HL; Bilger M; Khan AH; Clemens JD; Ebrahim S; Turner EL; ; Kasturiratne A
    Trials; 2017 Jun; 18(1):272. PubMed ID: 28606184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-benefit analysis of non-pharmacological treatment of hypertension.
    Johannesson M; Aberg H; Agréus L; Borgquist L; Jönsson B
    J Intern Med; 1991 Oct; 230(4):307-12. PubMed ID: 1919423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of hypertension treatment in Sweden.
    Johannesson M
    Pharmacoeconomics; 1995 Mar; 7(3):242-50. PubMed ID: 10155314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of age on the cost-effectiveness of hypertension treatment: an analysis of randomized drug trials.
    Johannesson M
    Med Decis Making; 1994; 14(3):236-44. PubMed ID: 7934710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.
    Johannesson M
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S23-6. PubMed ID: 8868040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost effectiveness of lipid lowering in Swedish primary health care. The CELL Study Group.
    Johannesson M; Borgquist L; Jönsson B; Lindholm LH
    J Intern Med; 1996 Jul; 240(1):23-9. PubMed ID: 8708587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit of treating hypertension.
    Jönsson BG
    J Hypertens Suppl; 1994 Dec; 12(10):S65-70. PubMed ID: 7769494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The financial cost of optimising blood pressure control.
    Shiner T; Simons L; Parkinson H; Khanbhai A; Karthikeyan VJ; Nandhara G; Beevers DG
    J Hum Hypertens; 2005 Jan; 19(1):83-4. PubMed ID: 15372065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a lifestyle programme on ambulatory blood pressure and drug dosage in treated hypertensive patients: a randomized controlled trial.
    Burke V; Beilin LJ; Cutt HE; Mansour J; Wilson A; Mori TA
    J Hypertens; 2005 Jun; 23(6):1241-9. PubMed ID: 15894901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A health-economic comparison of diet and drug treatment in obese men with mild hypertension.
    Johannesson M; Fagerberg B
    J Hypertens; 1992 Sep; 10(9):1063-70. PubMed ID: 1328366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.
    Augustovski F; Chaparro M; Palacios A; Shi L; Beratarrechea A; Irazola V; Rubinstein A; Mills K; He J; Pichon Riviere A
    Value Health; 2018 Dec; 21(12):1357-1364. PubMed ID: 30502778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines].
    Fender P; Guilhot J; Tilly B; Salanave B; Allemand H
    Therapie; 2001; 56(2):111-8. PubMed ID: 11471361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.